XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC ...Middle East

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for...

Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC )

Also on site :

• Russell Crowe, 61, Debuts a Svelte and Dapper Look at Wimbledon
• Dozens dead in pharmaceutical factory blast in southern India
• Elon Musk says Trump’s ‘Big Beautiful Bill’ could spell disaster for America. Here are its biggest pain points, according to critics